Myo-Inositol Effects on Pregnancy Outcomes and Fetal Growth: Myo-Inositol

Mukesh kumar; Harpreet  Singh; Tauhid  Iqbali; Ravi  Shah

doi:10.22270/ijmspr.v12i1.170

Authors

Mukesh Kumar MD, AIIMS Rishikesh, India https://orcid.org/0009-0001-0930-4612
Harpreet Singh MD, GMC Jammu, India https://orcid.org/0009-0002-8911-7768
Tauhid Iqbali MD, Patna Medical College, Patna, India
Ravi Shah MD, AIIMS Rishikesh, India

DOI:

https://doi.org/10.22270/ijmspr.v12i1.170

Keywords:

Myo-inositol, FGR, Preeclampsia, GDM

Abstract

Myo-inositol (MI), a naturally occurring carbocyclic sugar and second messenger in insulin signaling, has emerged as a supplement of interest in pregnancy due to its potential metabolic and reproductive effects. This review summarizes current evidence on MI supplementation during pregnancy, with special emphasis on maternal outcomes (e.g., gestational diabetes mellitus [GDM], hypertensive disorders), neonatal outcomes like preterm birth, birthweight, and implications for fetal growth.

Keywords: Myo-Inositol, GDM, Fetal growth, Diabetes

Author Biographies

Mukesh Kumar , MD, AIIMS Rishikesh, India

MD, AIIMS Rishikesh, India

Harpreet Singh , MD, GMC Jammu, India

MD, GMC Jammu, India

Tauhid Iqbali , MD, Patna Medical College, Patna, India

MD, Patna Medical College, Patna, India

Ravi Shah , MD, AIIMS Rishikesh, India

MD, AIIMS Rishikesh, India

References

.(1) A short history of inositol lipids - PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC5087877/

(2) Chhetri, D. R. Myo-Inositol and Its Derivatives: Their Emerging Role in the Treatment of Human Diseases. Front. Pharmacol. 2019;10:1172. https://doi.org/10.3389/fphar.2019.01172.

(3) Hughes, A. R.; Horstman, D. A.; Takemura, H.; Putney, J. W. Inositol Phosphate Metabolism and Signal Transduction. Am. Rev. Respir. Dis. 1990;141 (3 Pt 2):S115-118. https://doi.org/10.1164/ajrccm/141.3_Pt_2.S115.

(4) Downes, C. P.; Macphee, C. H. Myo-Inositol Metabolites as Cellular Signals. Eur. J. Biochem. 1990;193 (1):1–18. https://doi.org/10.1111/j.1432-1033.1990.tb19297.x.

(5) The insulin-sensitizing mechanism of myo-inositol is associated with AMPK activation and GLUT-4 expression in human endometrial cells exposed to a PCOS environment - PubMed. https://pubmed.ncbi.nlm.nih.gov/31874063/

(6) Tabatabaie, M.; Amiri, S.; Golestan Jahromi, M.; Sene, A. A.; Zandieh, Z.; Mehdizadeh, M.; Amjadi, F. The Effect of Myo-Inositol Supplement on Molecular Regulation of Folliculogenesis, Steroidogenesis, and Assisted Reproductive Technique Outcomes in Patients with Polycystic Ovarian Syndrome. Mol. Biol. Rep. 2022;49(2):875–884. https://doi.org/10.1007/s11033-021-06833-9.

(7) Bizzarri, M.; Fuso, A.; Dinicola, S.; Cucina, A.; Bevilacqua, A. Pharmacodynamics and Pharmacokinetics of Inositol(s) in Health and Disease. Expert Opin. Drug Metab. Toxicol. 2016;12(10):1181–1196. https://doi.org/10.1080/17425255.2016.1206887.

(8) Phelps, D. L.; Ward, R. M.; Williams, R. L.; Watterberg, K. L.; Laptook, A. R.; Wrage, L. A.; Nolen, T. L.; Fennell, T. R.; Ehrenkranz, R. A.; Poindexter, B. B.; Michael Cotten, C.; Hallman, M. K.; Frantz, I. D.; Faix, R. G.; Zaterka-Baxter, K. M.; Das, A.; Bethany Ball, M.; Michael O’Shea, T.; Backstrom Lacy, C.; Walsh, M. C.; Shankaran, S.; Sánchez, P. J.; Bell, E. F.; Higgins, R. D. Pharmacokinetics and Safety of a Single Intravenous Dose of Myo-Inositol in Preterm Infants of 23-29 Wk. Pediatr. Res. 2013;74(6):721–729. https://doi.org/10.1038/pr.2013.162.

(9) Carlomagno, G.; De Grazia, S.; Unfer, V.; Manna, F. Myo-Inositol in a New Pharmaceutical Form: A Step Forward to a Broader Clinical Use. Expert Opin. Drug Deliv. 2012;9(3):267–271. https://doi.org/10.1517/17425247.2012.662953.

(10) Matarrelli, B.; Vitacolonna, E.; D’Angelo, M.; Pavone, G.; Mattei, P. A.; Liberati, M.; Celentano, C. Effect of Dietary Myo-Inositol Supplementation in Pregnancy on the Incidence of Maternal Gestational Diabetes Mellitus and Fetal Outcomes: A Randomized Controlled Trial. J. Matern.-Fetal Neonatal Med. Off. J. Eur. Assoc. Perinat. Med. Fed. Asia Ocean. Perinat. Soc. Int. Soc. Perinat. Obstet. 2013;26(10):967–972. https://doi.org/10.3109/14767058.2013.766691.

(11) Wei, J.; Yan, J.; Yang, H. Inositol Nutritional Supplementation for the Prevention of Gestational Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients 2022;14(14):2831. https://doi.org/10.3390/nu14142831.

(12) Guo, X.; Guo, S.; Miao, Z.; Li, Z.; Zhang, H. Myo-Inositol Lowers the Risk of Developing Gestational Diabetic Mellitus in Pregnancies: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with Trial Sequential Analysis. J. Diabetes Complications 2018;32(3):342–348. https://doi.org/10.1016/j.jdiacomp.2017.07.007.

(13) Pharmacodynamics and pharmacokinetics of inositol(s) in health and disease - PubMed. https://pubmed.ncbi.nlm.nih.gov/27351907/

(14) Story, L.; Damodaram, M. S.; Supramaniam, V.; Allsop, J. M.; Mcguinness, A.; Patel, A.; Wylezinska, M.; Kumar, S.; Rutherford, M. A. Myo-Inositol Metabolism in Appropriately Grown and Growth-Restricted Fetuses: A Proton Magnetic Resonance Spectroscopy Study. Eur. J. Obstet. Gynecol. Reprod. Biol. 2013;170(1):77–81. https://doi.org/10.1016/j.ejogrb.2013.05.006.

(15) Dessì, A.; Fanos, V. Myoinositol: A New Marker of Intrauterine Growth Restriction? J. Obstet. Gynaecol. J. Inst. Obstet. Gynaecol. 2013;33(8):776–780. https://doi.org/10.3109/01443615.2013.831046.

(16) Myo-inositol moderates maternal BMI and glycemia related variations in in-vitro placental 13C-DHA-metabolism, altering their relationships with birthweight | Scientific Reports. https://www.nature.com/articles/s41598-022-18309-2

(17) van der Wel, A. W. T.; Frank, C. M. C.; Bout-Rebel, R.; Duijnhoven, R. G.; van Bree, B. E.; Valkenburg, O.; Al-Nasiry, S.; van Oppenraaij, R. H. F.; Vogelvang, T. E.; Westerhuis, M. E. M. H.; van de Nieuwenhof, H. P.; Gielen, S. C. J. P.; Bandell, M. L.; Bekker, M. N.; Wouters, M. G. A. J.; Mijatovic, V.; Franx, A.; Lambalk, C. B.; Broekmans, F. J. M.; de Weerd, S.; Gerards, J. M. H.; Baalman, J. H.; van Disseldorp, J.; Langenveld, J.; Gunning, M. N.; Frederix, G. W. J.; Painter, R. C.; Fauser, B. C. J. M.; Laven, J. S. E.; van Rijn, B. B. Myo-Inositol Supplementation to Prevent Pregnancy Complications in Polycystic Ovary Syndrome: A Randomized Clinical Trial. JAMA 2025;334(13):1151–1159. https://doi.org/10.1001/jama.2025.13668.